


RESEARCH REPORT



SYNDROMIC MULTIPLEX PANELS MARKETS.

Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place and by Product. With Market Analysis, Executive Guides and Customization. 2022 to 2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1 Market Guides22

1.1 Situation Analysis 23

1.2 Guide for Executives and Marketing Staff 26

1.3 Guide for Investment Analysts and Management Consultants..... 28

2 Introduction and Market Definition30

2.1 What are Syndromic Multiplex Tests? 31

2.2 Syndromic Testing – the quiet revolution in diagnostics 32

2.2.1 Syndromic Testing – more than Panels. 33

2.3 Market Definition 34

2.3.1 Multiplex Market Size..... 34

2.3.2 Currency. 34

2.3.3 Years..... 35

2.4 Methodology..... 36

2.4.1 Authors 36

2.4.2 Sources..... 36

2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic 37

2.5.1 Global Healthcare Spending 37

2.5.2 Spending on Diagnostics 39

2.5.3 Important Role of Insurance for Diagnostics..... 40

3 The Infectious Diseases – Guide to the Pathogens.....41

3.1 The Coronavirus..... 42

3.1.1 Severe acute respiratory syndrome (SARS) 44

3.1.2 Middle East respiratory syndrome (MERS) 46

- 3.1.3 COVID-19. The SARS CoV 2 Virus..... 47
 - 3.1.3.1 Signs and symptoms 48
 - 3.1.3.2 Transmission 49
 - 3.1.3.3 Diagnosis 50
 - 3.1.3.4 Prevention 52
 - 3.1.3.5 Management..... 53
 - 3.1.3.6 Prognosis..... 54
 - 3.1.3.7 New Strains and Subsequent Mutations 55
- 3.3 HIV - Human Immunodeficiency Virus (AIDS) 56
 - 3.3.1 Virology 56
 - 3.3.1.1 Classification 56
 - 3.3.1.2 Structure and genome..... 57
 - 3.3.1.3 Tropism..... 59
 - 3.3.1.4 Replication cycle..... 62
 - 3.3.1.5 Genetic variability 67
 - 3.3.2 Diagnosis 69
 - 3.3.3 Testing..... 70
 - 3.3.3.1 Antibody tests 70
 - 3.3.3.2 Point of Care Tests (POCT) 73
 - 3.3.3.3 Antigen Tests 76
 - 3.3.3.4 Nucleic acid-based tests (NAT) 76
 - 3.3.3.5 Other tests used in HIV treatment..... 77
- 3.4 HBV – Hepatitis B..... 79
 - 3.4.1 Virology 80
 - 3.4.1.1 Genome 81
 - 3.4.1.2 Pathogenesis..... 82

- 3.4.1.3 Hepatitis B virus replication 82
- 3.4.1.4 Serotypes and genotypes..... 83
- 3.4.2 Mechanisms..... 83
- 3.4.3 Diagnosis 84
- 3.4.4 Market Opportunity Analysis 85
- 3.5 HCV – Hepatitis C..... 87
 - 3.5.1 Taxonomy..... 88
 - 3.5.1.1 Structure 88
 - 3.5.1.2 Genome 89
 - 3.5.2 Molecular biology 90
 - 3.5.3 Replication..... 91
 - 3.5.4 Genotypes 93
 - 3.5.4.1 Clinical importance..... 93
 - 3.5.5 Market Opportunity Analysis 94
- 3.6 2.4 HPV - Human papillomavirus..... 95
 - 3.6.1 Virology 97
 - 3.6.1.1 E6/E7 proteins..... 97
 - 3.6.1.2 Role in cancer..... 97
 - 3.6.1.3 E2 research..... 98
 - 3.6.1.4 Latency period 99
 - 3.6.1.5 Clearance 99
 - 3.6.2 Diagnosis 100
 - 3.6.2.1 Cervical testing 100
 - 3.6.2.2 Oral testing 102
 - 3.6.2.3 Testing men 102
 - 3.6.2.4 Other testing 103

- 3.6.3 Market Opportunity Analysis 104
- 3.7 Influenza..... 110
 - 3.7.1 Virology 111
 - 3.7.1.1 Types of virus 111
 - 3.7.1.2 Influenzavirus A 111
 - 3.7.1.3 Influenzavirus B 112
 - 3.7.1.4 Influenzavirus C 113
 - 3.7.1.5 Structure, properties, and subtype nomenclature 113
 - 3.7.1.6 Replication 114
 - 3.7.2 Testing..... 117
 - 3.7.2.1 Advantages/Disadvantages of Molecular Assays..... 119
 - 3.7.3 Market Opportunity Analysis 120
- 3.8 CTGC - Chlamydia/Gonorhea 128
 - 3.8.1 Gonorrhoea 128
 - 3.8.1.1 Diagnosis 129
 - 3.8.1.2 Screening 129
 - 3.8.2 Chlamydia 129
 - 3.8.2.1 Diagnosis 130
 - 3.8.2.2 Screening 131
 - 3.8.3 Testing..... 132
 - 3.8.3.1 Nucleic acid amplification tests (NAATs)..... 132
 - 3.8.3.2 Performance of NAAT Tests..... 140
 - 3.8.4 Market Opportunity Analysis 141
- 3.9 Tuberculosis..... 143
 - 3.9.1 Mycobacteria..... 144
 - 3.9.2 Diagnosis 145

- 3.9.2.1 Active tuberculosis 145
- 3.9.2.2 Latent tuberculosis..... 146
- 3.9.3 Epidemiology..... 146
- 3.9.4 Molecular Diagnostic Tests 148
- 3.9.5 Market Opportunity Analysis 149
- 3.10 MRSA - Methicillin-resistant Staphylococcus aureus 151
 - 3.10.1 Diagnosis 151
 - 3.10.2 FDA Approved Molecular Tests 152
 - 3.10.3 Market Opportunity Analysis 153
- 3.11 VRE - Vancomycin-resistant Enterococcus 154
 - 3.11.1 FDA Approved MDx Tests for VRE..... 155
 - 3.11.2 Market Opportunity Analysis 156
- 4 Industry Overview..... 157
 - 4.1 Industry Participants 158
 - 4.1.1 IVD Supplier..... 158
 - 4.1.2 Independent lab specialized/esoteric 159
 - 4.1.3 Independent lab national/regional..... 159
 - 4.1.4 Independent lab analytical 160
 - 4.1.5 Public National/regional lab 160
 - 4.1.6 Hospital lab 160
 - 4.1.7 Physician lab..... 161
 - 4.1.8 Audit body 161
 - 4.2 The Clinical Laboratory Market Segments 163
 - 4.2.1 Traditional Market Segmentation..... 163
 - 4.2.2 Laboratory Focus and Segmentation..... 164
 - 4.2.3 Segmenting the Syndromic Testing Market..... 165

- 4.3 Industry Structure..... 167
 - 4.3.1 Hospital Testing Share 167
 - 4.3.2 Economies of Scale..... 167
 - 4.3.2.1 Hospital vs. Central Lab..... 168
 - 4.3.3 Physician Office Lab's..... 169
 - 4.3.4 Physician's and POCT 169
- 5 Market Trends171
 - 5.1 Factors Driving Growth 172
 - 5.1.1 Speed of Diagnosis..... 172
 - 5.1.2 Effect of Syndromic Testing on Costs..... 173
 - 5.1.3 Point of Care Advantage..... 173
 - 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk..... 173
 - 5.1.5 Single Visits. 173
 - 5.1.6 Improvement in Outcomes. 174
 - 5.1.7 Impact of the COVID-19 Pandemic. 174
 - 5.2 Factors Limiting Growth 175
 - 5.2.1 Lower Prices. 175
 - 5.2.2 Administration/reimbursement..... 176
 - 5.2.3 Infectious Disease is Declining But..... 178
 - 5.2.4 Wellness Hurts..... 178
 - 5.2.5 Economic Growth improves Living Standards. 178
 - 5.2.6 Impact of the Pandemic Recession 179
 - 5.3 Instrumentation and Automation 180
 - 5.3.1 Instruments Key to Market Share 180
 - 5.3.2 The Shrinking Machine. 180
 - 5.3.3 Syndrome Testing Moving to Big Instruments? 180

- 5.4 Diagnostic Technology Development 182
 - 5.4.1 Syndromictrends.com..... 182
 - 5.4.2 Comparing Syndrome and Targeted Testing 183
 - 5.4.3 The Multiplex Paradigm Shift..... 184
 - 5.4.4 The Sepsis Testing Market – Bellwether for Syndromics..... 185
 - 5.4.5 The Single Visit and AntiMicrobial Resistance 185
 - 5.4.6 Syndromics drives POCT adoption..... 186
 - 5.4.7 A Big Future for PCR? 186
- 6 Syndromic Testing Recent Developments 188
 - 6.1 Recent Developments – Importance and How to Use This Section 189
 - 6.1.1 Importance of These Developments 189
 - 6.1.2 How to Use This Section..... 189
 - 6.2 Genetic Signatures Wins Public Health Wales Contract..... 189
 - 6.3 Qiagen Looks to Long-Term Growth..... 190
 - 6.4 LexaGene Gets Investment 194
 - 6.5 Seegene Multiplex COVID-19/Flu/RSV Test Receives Approval..... 195
 - 6.6 BforCure to Adapt Rapid PCR Platform for Cancer..... 196
 - 6.7 Accelerated Growth for Decentralized Testing 196
 - 6.8 QuantuMDx Developing Syndromic Panels for European Launch..... 204
 - 6.9 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel..... 209
 - 6.10 QuantumDx Gets CE Mark for Rapid PoC PCR System..... 209
 - 6.11 Bio-Rad Laboratories, Seegene Partner for MDx Development..... 211
 - 6.12 Baebies to Expand Finder Platform..... 211
 - 6.13 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio 215
 - 6.14 Binx Health Targeting Clinics, DTC & OTC With STI Tests 219
 - 6.15 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV 223

6.16 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic 224

6.17 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test 227

6.18 New Approach Involves Silicon-Based Test for Infectious Disease Screening 228

6.19 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test 233

6.20 Qiagen sees NeuMoDx as Growth Vehicle 236

6.21 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround 240

6.22 Roche, Speedx Partner to Expand Access to Antibiotic Resistance Tests 244

6.23 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU 244

6.24 Infectious Disease Testing Firm Curative Acquires KorvaLabs 245

6.25 ChromaCode Raises Additional \$10M 246

6.26 COVID-19 Patients Need Syndromic Testing 246

6.27 GenMark Diagnostics – New Respiratory Panel due in June 248

6.28 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark 249

6.29 Exact Diagnostics launches respiratory panel control 250

6.30 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA 251

6.31 Nanomix Receives CE Mark for Diagnostic 252

6.32 Applied BioCode Applies to FDA for Syndromic Respiratory Panel 253

6.33 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC 255

6.34 QIAGEN's New GI Panel Performance Assessed 255

6.35 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA 257

6.36 Applied BioCode Obtains FDA Clearance 258

6.37 Meridian Bioscience to Acquire GenePOC Inc 258

6.38 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance 259

6.39 Qiagen gets FDA clearance for syndromic testing system 261

6.40 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux 262

6.41 Akonni Biosystems Submits Multiplex Diagnostics System to FDA 262

6.42	Ador Diagnostic to receive \$30M in Funding for 100-Plex PoC	264
6.43	SAW Diagnostics Receives Funding for Commercialisation of PoC Platform.....	265
6.44	QuantuMDx and Molbio announce MoU	267
6.45	Immunexpress Wins \$745K Contract for Rapid Sepsis Assay	268
6.46	Mobidiag Inks European, Middle Eastern Distribution Deals.....	269
6.47	BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial	269
7	Profiles of Key Syndromic Testing Companies	271
7.1	Abacus Diagnostica	272
7.2	Abbott Diagnostics	273
7.3	Accelerate Diagnostics	275
7.4	Ador Diagnostics	276
7.5	Akonni Biosystems	277
7.6	Alveo Technologies.....	278
7.7	Antelope Dx.....	279
7.8	Applied BioCode	280
7.9	Aus Diagnostics	281
7.10	Baebies	282
7.11	Beckman Coulter Diagnostics.....	284
7.12	Becton, Dickinson and Company	285
7.13	Binx Health	287
7.14	Biocartis.....	289
7.15	BioFire Diagnostics (bioMérieux)	290
7.16	bioMérieux Diagnostics.....	292
7.17	Bio-Rad Laboratories, Inc.....	294
7.18	Bosch Healthcare Solutions GmbH.....	296
7.19	Cepheid (Danaher)	297

7.20	Credo Diagnostics Biomedical	299
7.21	Cue Health.....	300
7.22	Curetis N.V. / Curetis GmbH.....	302
7.23	Diagenode Diagnostics	303
7.24	Diasorin S.p.A.	304
7.25	Enzo Life Sciences, Inc.	306
7.26	Eurofins Scientific	308
7.27	Fluxergy	310
7.28	Fusion Genomics.	311
7.29	Genetic Signatures.....	313
7.30	GenMark Dx (Roche)	314
7.31	Hibergene Diagnostics.....	316
7.32	Hologic	317
7.33	Immunexpress.....	319
7.34	Inflammatix	320
7.35	Invetech.....	321
7.36	Janssen Diagnostics	322
7.37	Karius	323
7.38	Lexagene	325
7.39	LightDeck Diagnostics	326
7.40	Lucira Health.....	327
7.41	Luminex Corp	328
7.42	Maxim Biomedical	330
7.43	Meridian Bioscience.....	331
7.44	Mesa Biotech (Thermo Fisher)	333
7.45	Millipore Sigma	334

7.46 Mobidiag (Hologic) 335

7.47 Molbio Diagnostics 336

7.48 Nanomix 337

7.49 Novel Microdevices 338

7.50 Operon 339

7.51 Oxford Nanopore Technologies 340

7.52 Panagene 341

7.53 Perkin Elmer 342

7.54 Primerdesign (Novacyt) 344

7.55 Prominex 345

7.56 Qiagen Gmbh 346

7.57 Quantumdx 348

7.58 Quidel 349

7.59 Roche Molecular Diagnostics 351

7.60 Saw Diagnostics 353

7.61 Seegene 354

7.62 Siemens Healthineers 356

7.63 Sona Nanotech 358

7.64 SpeedX 359

7.65 T2 Biosystems 360

7.66 Talis Biomedical 361

7.67 Thermo Fisher Scientific Inc. 362

7.68 Veramarx 364

7.69 Visby Medical 365

7.70 XCR Diagnostics 367

8 The Global Market for Syndromic Multiplex Diagnostics 368

- 8.1 Global Market Overview by Country 369
 - 8.1.1 Table – Global Market by Country..... 369
 - 8.1.2 Chart - Global Market by Country 370
- 8.2 Global Market by Syndrome - Overview 371
 - 8.2.1 Table – Global Market by Syndrome 371
 - 8.2.2 Chart – Global Market by Syndrome – Base/Final Year Comparison 372
 - 8.2.3 Chart – Global Market by Syndrome – Base Year 373
 - 8.2.4 Chart – Global Market by Syndrome – End Year 374
 - 8.2.5 Chart – Global Market by Syndrome – Share by Year 375
 - 8.2.6 Chart – Global Market by Syndrome – Segments Growth..... 376
- 8.3 Global Market by Place - Overview 377
 - 8.3.1 Table – Global Market by Place..... 377
 - 8.3.2 Chart – Global Market by Place – Base/Final Year Comparison 378
 - 8.3.3 Chart – Global Market by Place – Base Year..... 379
 - 8.3.4 Chart – Global Market by Place – End Year 380
 - 8.3.5 Chart – Global Market by Place – Share by Year..... 381
 - 8.3.6 Chart – Global Market by Place – Segments Growth 382
- 8.4 Global Market by Product - Overview 383
 - 8.4.1 Table – Global Market by Product..... 383
 - 8.4.2 Chart – Global Market by Product – Base/Final Year Comparison..... 384
 - 8.4.3 Chart – Global Market by Product – Base Year 385
 - 8.4.4 Chart – Global Market by Product – End Year 386
 - 8.4.5 Chart – Global Market by Product – Share by Year 387
 - 8.4.6 Chart – Global Market by Product – Segments Growth 388
- 9 Global Syndromic Multiplex Markets – By Syndrome389
 - 9.1 Respiratory 390

9.1.1 Table Respiratory – by Country 390

9.1.2 Chart - Respiratory Growth..... 391

9.2 Gastrointestinal..... 392

9.2.1 Table Gastrointestinal – by Country 392

9.2.2 Chart - Gastrointestinal Growth 393

9.3 Blood 394

9.3.1 Table Blood – by Country 394

9.3.2 Chart - Blood Growth..... 395

9.4 Meningitis/Encephalitis 396

9.4.1 Table Meningitis/Encephalitis – by Country..... 396

9.4.2 Chart - Meningitis/Encephalitis Growth 397

9.5 Sexually Transmitted Disease..... 398

9.5.1 Table Sexually Transmitted Disease – by Country 398

9.5.2 Chart – Sexually Transmitted Disease Growth..... 399

9.6 Other Syndrome 400

9.6.1 Table Other – by Country 400

9.6.2 Chart - Other Growth..... 401

10 Global MDx Infectious Disease Markets – by Place402

10.1 Hospital Lab 403

10.1.1 Table Hospital Lab – by Country 403

10.1.2 Chart - Hospital Lab Growth..... 404

10.2 Outpatient Lab..... 405

10.2.1 Table Outpatient Lab – by Country 405

10.2.2 Chart - Outpatient Lab Growth 406

10.3 Point of Care..... 407

10.3.1 Table Point of Care – by Country..... 407

- 10.3.2 Chart – Point of Care Growth..... 408
- 10.4 Other Place 409
 - 10.4.1 Table Other – by Country 409
 - 10.4.2 Chart - Other Place Growth 410
- 11 Global MDx Infectious Disease Markets – by Product411
 - 11.1 Instruments 412
 - 11.1.1 Table Instruments – by Country 412
 - 11.1.2 Chart - Instruments Growth..... 413
 - 11.2 Cartridges 414
 - 11.2.1 Table Cartridges – by Country 414
 - 11.2.2 Chart - Cartridges Growth..... 415
 - 11.3 Reagents..... 416
 - 11.3.1 Table Reagents – by Country 416
 - 11.3.2 Chart - Reagents Growth 417
 - 11.4 Other Product..... 418
 - 11.4.1 Table Other Product – by Country 418
 - 11.4.2 Chart – Other Product Growth..... 419
- 12 Appendices420
 - 12.1 United States Medicare System: 2022 Clinical Laboratory Fees Schedule..... 421

Table of Tables

Table 1 Characteristics of Coronavirus Pandemic Infections 47

Table 2 COVID-19 Symptoms..... 49

Table 3 Classification of HIV Species..... 57

Table 4 HBV Tests - CMS Codes & Prices..... 87

Table 5 HCV Tests - CMS Codes & Prices 94

Table 6 HPV Clearance Rates 100

Table 7 HPV Tests - CMS Codes & Prices..... 105

Table 8 HPV Tests, Technology, Types 106

Table 9 Types of Influenza Tests 117

Table 10 Influenza Tests - CMS Codes & Prices..... 120

Table 11 FDA Cleared Molecular Assays for Influenza 121

Table 12 FDA Cleared NAAT CTGC Tests 133

Table 13 CTGC NAAT Target Sequences and Possible False Reactions 138

Table 14 Influenza Tests - CMS Codes & Prices..... 142

Table 15 FDA Approved MDx Tests for Tuberculosis 148

Table 16 Tuberculosis Tests - CMS Codes & Prices..... 149

Table 17 FDA Approved Tests for MRSA 152

Table 18 MRSA Tests - CMS Codes & Prices 154

Table 19 FDA Approved Tests for VRE 155

Table 20 VRE Tests - CMS Codes & Prices 156

Table 21 Market Players by Type 158

Table 22 Clinical Laboratory Departments and Segments 163

Table 23 Laboratory Management Focus – Different Approaches 164

Table 24 Key Segmentation Variables Going Forward..... 165

Table 25 Possible Market Segments of Syndromic Multiplex Market 165

Table 26 Five Factors Driving Growth 172

Table 27 How SMT Improves Outcomes..... 174

Table 28 Four Factors Limiting Growth 175

Table 29 - Global Market by Region 369

Table 30 Global Market by Syndrome 371

Table 31 Global Market by Place..... 377

Table 32 Global Market by Product 383

Table 33 Respiratory by Country..... 390

Table 34 Gastrointestinal by Country 392

Table 35 Blood by Country..... 394

Table 36 Meningitis/Encephalitis by Country..... 396

Table 37 Sexually Transmitted Disease by Country 398

Table 38 Other by Country..... 400

Table 39 Hospital Lab by Country 403

Table 40 Outpatient Lab by Country 405

Table 41 Point of Care by Country 407

Table 42 Other by Country..... 409

Table 43 Instruments by Country 412

Table 44 Cartridges by Country..... 414

Table 45 Reagents by Country 416

Table 46 Other Product by Country 418

Table 47 2022 Clinical Lab Fee Schedule 421

Table of Figures

Figure 1 The Global Healthcare Spending Picture..... 38

Figure 3 The Lab Test Pie 39

FIGURE 3 STRUCTURE OF CORONAVIRUSES 43

Figure 4 HIV Virion 58

Figure 5 Diagram of the HIV Replication Cycle 62

Figure 6 The Structure of the HBV Virus..... 81

Figure 7 Hepatitis B Replication 82

Figure 8 Structure of the HCV Virus..... 89

Figure 9 HCV Replication Cycle 92

Figure 10 Structure of the Influenza Virion 114

Figure 11 Influenza Replication..... 115

Figure 12 Scanning Electronmicrograph of Tuberculosis..... 144

Figure 13 Chart Death Rates and Infectious Disease Decline 177

Figure 14 Comparing Syndromic and Targeted Testing..... 183

Figure 16 The Multiplex Paradigm Shift..... 184

Figure 16 Global Market Share Chart 370

Figure 17 Global Market by Syndrome - Base vs. Final 372

Figure 18 Global Market by Syndrome Base Year 373

Figure 19 Global Market by Syndrome End Year 374

Figure 20 Syndrome Share by Year 375

Figure 21 Syndrome Segments Growth..... 376

Figure 22 Global Market by Place - Base vs. Final..... 378

Figure 23 Global Market by Place Base Year..... 379

Figure 24 Global Market by Place End Year 380

Figure 25 Place Share by Year 381

Figure 26 Place Segments Growth 382

Figure 27 Global Market by Product - Base vs. Final..... 384

Figure 28 Global Market by Product Base Year 385

Figure 29 Global Market by Product End Year..... 386

Figure 30 Product Share by Year 387

Figure 31 Product Segments Growth 388

Figure 32 Respiratory Growth..... 391

Figure 33 Gastrointestinal Diagnostics Growth..... 393

Figure 34 Blood Growth..... 395

Figure 35 Meningitis/Encephalitis Growth..... 397

Figure 36 Sexually Transmitted Disease Growth 399

Figure 37 Other Growth..... 401

Figure 38 Hospital Lab Growth..... 404

Figure 39 Outpatient Lab Growth 406

Figure 40 Point of Care Growth 408

Figure 41 Other Growth..... 410

Figure 42 Instruments Growth 413

Figure 43 Cartridges Growth..... 415

Figure 44 Reagents Growth 417

Figure 45 Other Product Growth 419

2.1 What are Syndromic Multiplex Tests?

Syndromic Multiplex tests identify many infectious diseases with a single test.

Syndromic Multiplex Tests (SMT) are single tests that report back on the presence, or not, of several infectious diseases at the same time. Today the pattern is for a doctor, when faced with a patient who has some kind of cold/flu for instance, (a respiratory syndrome) to make a preliminary diagnosis and then to order a limited number, or just one, test to see if the diagnosis is correct. This is the traditional approach that goes back to the days when not all infectious diseases were known and they were recognized instead by their symptoms. The laboratory was used to confirm, or not, the diagnosis and often the disease was treated, and still is today, before the laboratory results were in. Tests were considered to be expensive and were ordered only as needed and often not at all.

These tests are DNA based and consequently are more accurate and specific.

The revolution in genetic knowledge has created technologies that can recognize multiple pathogens using a single test. This is called a multiplex test. The technology is DNA based so these tests tend to be very much more accurate than traditional testing methods. And because of this DNA base the possibility exists of identifying specific classes of pathogens, e.g. those resistant to certain antibiotics or susceptible to other antibiotics.

A syndrome is a group of symptoms that are often seen together and suggest the presence of one or more infectious diseases. The GI-Enteric Syndrome for instance, might often just be referred to by its main symptom, diarrhea. So diagnostic tests are being developed that test for a wide range of pathogens, in a single test, that might cause this symptom. This Syndromic Multiplex testing approach costs more initially, sometimes a lot more, but despite that is proving very popular.

Suppliers are providing different tests for different syndromes with different pathogens identified. These can be performed on smaller proprietary instruments and sometimes on traditional laboratory instruments. This has created a complicated dynamic market with new tests and new instruments being frequently announced.

3.1.2 Middle East respiratory syndrome (MERS)

In September 2012, a new type of coronavirus was identified, initially called Novel Coronavirus 2012, and now officially named Middle East respiratory syndrome coronavirus (MERS-CoV). WHO issued a global alert soon after. The WHO update on 28 September 2012 stated that the virus did not seem to pass easily from person to person. However, on 12 May 2013, a case of human-to-human transmission in France was confirmed by the French Ministry of Social Affairs and Health. In addition, cases of human-to-human transmission were reported by the Ministry of Health in Tunisia. Two confirmed cases involved people who seemed to have caught the disease from their late father, who became ill after a visit to Qatar and Saudi Arabia. Despite this, it appears that the virus had trouble spreading from human to human, as most individuals who are infected do not transmit the virus. By 30 October 2013, there were 124 cases and 52 deaths in Saudi Arabia.

After the Dutch Erasmus Medical Centre sequenced the virus, the virus was given a new name, Human Coronavirus–Erasmus Medical Centre (HCoV-EMC). The final name for the virus is Middle East respiratory syndrome coronavirus (MERS-CoV). In May 2014, the only two United States cases of MERS-CoV infection were recorded, both occurring in healthcare workers who worked in Saudi Arabia and then traveled to the U.S. One was treated in Indiana and one in Florida. Both of these individuals were hospitalized temporarily and then discharged.

In May 2015, an outbreak of MERS-CoV occurred in the Republic of Korea, when a man who had traveled to the Middle East, visited 4 hospitals in the Seoul area to treat his illness. This caused one of the largest outbreaks of MERS-CoV outside the Middle East. As of December 2019, 2,468 cases of MERS-CoV infection had been confirmed by laboratory tests, 851 of which were fatal, a mortality rate of approximately 34.5%.

5.4.2 Comparing Syndrome and Targeted Testing

Syndromic testing, and its popularity, represent a shift in thinking about diagnosis. Traditionally diagnosis is done by a doctor with the lab tests confirming (or not) the diagnosis. In the syndromic testing paradigm, *the diagnosis shifts to the lab*. The doctor, recognizing the limits of their craft, lets the lab do the real work, and often saves physician time in the process. It is no wonder that time pressed Emergency Room physicians are enthusiastic adopters. Working against this is a very traditional view, control costs by stopping physicians from ordering unnecessary and expensive tests. This narrow view ignores the broader cost picture and the goal of the medical system, better care.




FIGURE 14 COMPARING SYNDROMIC AND TARGETED TESTING

6.1 Recent Developments – Importance and How to Use This Section

6.1.1 Importance of These Developments

Many users, especially those in the financial community, have noted that this section of the report can be extremely valuable in helping to understand industry current events and the evolution of key market players. These items are not chosen at random. They have been selected by the author(s) as significant and worth reading about, i.e. important. Please keep this in mind in reviewing them.

6.1.2 How to Use This Section

These items are NOT in date order. They are in the order in which they have been added to the report. This report is updated regularly, and new items are incorporated, and others removed. Please refer to the date of an item to understand its currency. Reading this entire section is recommended for those not familiar with the industry. Many of the trends and issues noted elsewhere are illustrated in these actual events.

6.2 Genetic Signatures Wins Public Health Wales Contract

Mar 30, 2022

Australian infectious disease molecular diagnostics developer Genetic Signatures said on Wednesday that it has won a tender for a three-year contract with Public Health Wales to provide molecular detection of enteric pathogens. Under the contract, worth up to \$1.8 million (US\$1.4 million) per year, Genetic Signatures will provide its EasyScreen enteric real-time PCR testing kits and instruments to seven sites within Wales.

EasyScreen enteric qPCR is a CE-marked flexible syndromic test that can detect more than 20 clinically relevant pathogenic bacteria, protozoan, and viral agents that cause gastroenteritis symptoms, the firm said in a statement.

The assay uses Genetic Signatures' proprietary 3base technology, which employs bisulfite treatment to reduce complexity between subtypes or strains without compromising specificity.

Genetic Signatures recently joined the BioHub Birmingham as the launchpad for a planned further expansion into Europe, the Middle East, and Africa.

7.9 Aus Diagnostics

www.ausdiagnostics.com

290-292 Coward Street

Mascot NSW 2020

Australia

TEL. +61 2 9698 8030

Description:

Revenue: ~\$7.5M

This privately held company was founded in 2006 by the current Managing Director. The company offers a wide range of syndromic multiplexing kits using a distributor strategy with offices in the UK and New Zealand. The company is active in a wide range of markets beyond human medical syndromic multiples testing, including veterinary and environmental assay markets.

The company offers a robust kit product line with several panel options in each of the following Syndrome categories

Respiratory w C19 dx

GI Enteric

Sexually Transmitted Disease

Parasites

Bacterial Resistance

HPV

8.3.2 Chart – Global Market by Place – Base/Final Year Comparison

Revenues are base year US\$ millions and do NOT include inflation.

Legend removed for sample.




FIGURE 22 GLOBAL MARKET BY PLACE - BASE VS. FINAL

9.1 Respiratory

9.1.1 Table Respiratory – by Country

Revenues are base year US\$ millions and do NOT include inflation.

TABLE 33 RESPIRATORY BY COUNTRY

	2021	2022	2023	2024	2025	2026	CAGR
USA	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Canada	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Germany	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
France	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
UK	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
RoEUR	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Japan	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
China	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
S Korea	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
RoAP	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Brazil	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Mexico	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
RoLA	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
ME&A	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX
Global	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX	XXXX